These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18779277)

  • 1. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study.
    Kim JY; Hyun YJ; Jang Y; Lee BK; Chae JS; Kim SE; Yeo HY; Jeong TS; Jeon DW; Lee JH
    Am J Clin Nutr; 2008 Sep; 88(3):630-7. PubMed ID: 18779277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of V279F in the Lp-PLA(2) gene on markers of oxidative stress and inflammation in Koreans.
    Paik JK; Chae JS; Jang Y; Kim JY; Kim OY; Jeong TS; Lee SH; Lee JH
    Clin Chim Acta; 2010 Apr; 411(7-8):486-93. PubMed ID: 20080080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.
    Hatoum IJ; Nelson JJ; Cook NR; Hu FB; Rimm EB
    Am J Clin Nutr; 2010 Mar; 91(3):786-93. PubMed ID: 20107195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians.
    Anuurad E; Ozturk Z; Enkhmaa B; Pearson TA; Berglund L
    J Clin Endocrinol Metab; 2010 May; 95(5):2376-83. PubMed ID: 20194707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
    Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).
    Paik JK; Kim JY; Kim OY; Lee Y; Jeong TS; Sweeney G; Jang Y; Lee JH
    PLoS One; 2012; 7(2):e29675. PubMed ID: 22359537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up.
    Rallidis LS; Tellis CC; Lekakis J; Rizos I; Varounis C; Charalampopoulos A; Zolindaki M; Dagres N; Anastasiou-Nana M; Tselepis AD
    J Am Coll Cardiol; 2012 Nov; 60(20):2053-60. PubMed ID: 23083783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome.
    Chae JS; Kim OY; Paik JK; Kang R; Seo WJ; Jeong TS; Sweeney G; Lee SH; Lee JH
    Atherosclerosis; 2011 Oct; 218(2):499-506. PubMed ID: 21762913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial variation in lipoprotein-associated phospholipase A₂ in older adults.
    Lee KK; Fortmann SP; Varady A; Fair JM; Go AS; Quertermous T; Hlatky MA; Iribarren C
    BMC Cardiovasc Disord; 2011 Jun; 11():38. PubMed ID: 21714927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.
    Miller RG; Costacou T; Orchard TJ
    Diab Vasc Dis Res; 2010 Jan; 7(1):47-55. PubMed ID: 20368232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitus.
    Garg S; Madhu SV; Suneja S
    Indian J Med Res; 2015 Jan; 141(1):107-14. PubMed ID: 25857502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease.
    Epps KC; Wilensky RL
    J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.
    Chung H; Kwon HM; Kim JY; Yoon YW; Rhee J; Choi EY; Min PK; Hong BK; Rim SJ; Yoon JH; Lee SJ; Park JK; Kim MH; Jo M; Yang JH; Lee BK
    Yonsei Med J; 2014 Nov; 55(6):1507-15. PubMed ID: 25323886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.
    Blake GJ; Dada N; Fox JC; Manson JE; Ridker PM
    J Am Coll Cardiol; 2001 Nov; 38(5):1302-6. PubMed ID: 11691499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.
    Suzuki T; Solomon C; Jenny NS; Tracy R; Nelson JJ; Psaty BM; Furberg C; Cushman M
    Circ Heart Fail; 2009 Sep; 2(5):429-36. PubMed ID: 19808373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual activity of serum lipoprotein-associated phospholipase A(2) yielding positive and inverse associations with cardiometabolic risk.
    Onat A; Hergenç G; Can G; Uğur M; Nartop F
    Clin Chem Lab Med; 2011 Aug; 49(8):1349-1357. PubMed ID: 21756164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.
    Iwase M; Sonoki K; Sasaki N; Ohdo S; Higuchi S; Hattori H; Iida M
    Atherosclerosis; 2008 Feb; 196(2):931-6. PubMed ID: 17350631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.
    Tsimikas S; Mallat Z; Talmud PJ; Kastelein JJ; Wareham NJ; Sandhu MS; Miller ER; Benessiano J; Tedgui A; Witztum JL; Khaw KT; Boekholdt SM
    J Am Coll Cardiol; 2010 Sep; 56(12):946-55. PubMed ID: 20828647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Caslake MJ; Packard CJ; Robertson M; Cooney J; Nelson JJ; Ford I; Gaw A; Jukema JW; Macfarlane PW; Stott DJ; Shepherd J;
    Atherosclerosis; 2010 May; 210(1):28-34. PubMed ID: 20005516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.